AXSM Axsome Therapeutics Inc.

85.2
-2.56  -3%
Previous Close 87.76
Open 87.78
Price To Book 473.33
Market Cap 3,153,698,107
Shares 37,015,236
Volume 530,949
Short Ratio
Av. Daily Volume 1,532,495
Stock charts supplied by TradingView

NewsSee all news

  1. Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

    NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  2. Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer's Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

    Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome's pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia Esreboxetine met primary

  3. Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response

    Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p<0.001) and freedom from most bothersome symptom (p=0.002) at 2 hours, compared to placebo Demonstrated superiority to

  4. Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) ("Axsome" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for the management of central

  5. Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock

    NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) ("Axsome" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for the management of central

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data met primary endpoint - April 15, 2019.
AXS-05
Smoking cessation
Phase 2/3 top-line data due 1H 2020.
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 data due 1Q 2020.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 trial met co-primary endpoints - December 30, 2019. NDA filing due 2H 2020.
AXS-07 - MOMENTUM
Migraine
Phase 3 data released December 16, 2019 met primary endpoint. NDA filing due 2H 2020.
AXS-05 -GEMINI
Major Depressive Disorder
Phase 2 data met primary endpoint - December 3, 2019. Phase 3 trial to be initiated 2020.
AXS-12
Narcolepsy
Phase 3 data due 1Q 2020.
AXS-07 - INTERCEPT
Migraine
Phase 3 trial met primary endpoints.
Esreboxetine (AXS-14)
Fibromyalgia

Latest News

  1. Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

    NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  2. Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer's Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

    Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome's pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia Esreboxetine met primary

  3. Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response

    Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p<0.001) and freedom from most bothersome symptom (p=0.002) at 2 hours, compared to placebo Demonstrated superiority to

  4. Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) ("Axsome" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for the management of central

  5. Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock

    NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) ("Axsome" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for the management of central

  6. Axsome Therapeutics Announces Proposed Public Offering of Common Stock

    NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) ("Axsome" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for the management of central

  7. Axsome Therapeutics Added to NASDAQ Biotechnology Index

    NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  8. Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder

    Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint) Statistically significant improvement at

  9. Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

    Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS; p<0.001 on

  10. Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine

    Company to host conference call on Monday, November 25 at 9:00 AM Eastern NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company

  11. Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient screening in

  12. Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine

    Majority of physicians indicate improved efficacy is most significant unmet need in the acute treatment of migraine Majority of physicians would be more likely to prescribe AXS-07 over current and other emerging

  13. Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy

    NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,

  14. Axsome Therapeutics to Provide Update on Continued Progress at the 2019 Cantor Global Healthcare Conference

      GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD on track for readout of topline results in 4Q 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD on track for readout of topline results in 4Q 2019 MOMENTUM Phase 3

  15. Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society

    Dual mechanisms, rapid absorption and long half-life support therapeutic potential of AXS-07 in migraine AXS-07 MOMENTUM Phase 3 trial ongoing in migraine patients with history of inadequate response to prior acute

  16. Innovative Drug-Delivery Systems Benefit Patients and Businesses

    NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often

  17. Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,